Explore the Agenda
8:00 am Check In & Registration
9:00 am Investment & Partnership Panel – Accelerating Innovation in Conjugate Therapeutics
Hear directly from VCs and pharma BD leaders on what data packages, formats, and strategies attract investment:
- What pharma wants: therapeutic index, MoA clarity, and early efficacy signals
- Pre-IND vs. Phase I: where investors draw the line on risk
- Collaboration models and platform licensing strategies
10:00 am Navigating the ADC Patent Landscape: Strategic Approaches to Taking Advantage of Key ADC Patent Expirations & Building ADC Patent Assets With & Without Traditional Payloads
- Analyzing the implications of traditional payload patent expiration on ADC development strategy
- Understanding opportunities for medicinal chemistry modifications to create novel IP around off-patent payloads
- Exploring strategic approaches to protecting novel ADC candidates and evaluating potential candidates against the patent landscape
10:30 am Deep Diving Into the Next Wave of ADC & XDC Design & Payload Innovation
- Breaking down the exciting landscape of novel drug conjugate design and mechanism of action
- Exploring emerging trends across drug conjugate design and targets
- Spotlighting novel conjugate innovation across multi payload ADCs, bispecific ADCs, and degrader conjugates
11:00 am Morning Break & Networking
Beyond Oncology - Advancing Bioconjugates in Immunology, Inflammation & Neurology
11:30 am Looking Beyond Oncology: Investigating Development & Delivery of AOCs Against Neuromuscular Disorders
- Exploring the FORCE modular drug delivery approach to enable widespread distribution of AOCs and chemically diverse therapeutic payloads to muscle and the CNS
- Assessing clinical data from DYNE-101 ACHIEVE trial in patients with DM1 and DYNE-251 DELIVER trial against DMD
- Contextualising how the encouraging clinical data and preclinical efficacy in FSHD and Pompe models supports the potential of FORCETM and AOCs to address neuromuscular disorders with high unmet medical needs
12:00 pm Expanding Bioconjugate Applications into Immunology & Inflammatory Disease
- Applying conjugate technology to autoimmune and fibrotic conditions
- Exploring payload classes with immune-modulating potential
- Understanding translational challenges beyond oncology targets
12:30 pm Unlocking the Potential of Novel Bioconjugates in Neurology & Rare Disease
- Leveraging small-format and peptide conjugates for BBB penetration
- Assessing preclinical models for neuro-targeted delivery
- Evaluating payload compatibility for CNS indications
1:00 pm Lunch
Exploring Strategies for Unlocking Success with Immune- Stimulating Payloads
2:00 pm Dual-Payload ADCs to Enhance Anti-Tumor Immune Response and Overcome Payload Resistance
- Utilizing an innovative cell-free platform to create site-selective, high DAR, novel dual-payload ADCs with favorable pharmacokinetics
- Showcasing dual-payload ADCs with superior preclinical in vitro and in vivo efficacy to overcome acquired single-payload resistance
- Demonstrating an immunostimulatory-cytotoxin dual-payload ADC with enhanced efficacy and therapeutic potential
2:30 pm Enhancing the Therapeutic Window for Oligo Payloads in Cancer
- Integrating saRNA and siRNA payloads into antibody conjugates
- Managing immunogenicity and safety considerations
- Identifying the next wave of oligonucleotide drug conjugate candidates